Precision Biosciences, Inc. · NASDAQ:DTIL
Precision Biosciences — Corporate Update (November 2025)
43 slides from Precision Biosciences's corporate update, November 2025
Slide 1: AASLD 2025 Business Update
AASLD 2025 Business Update November 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, as may any related presentations, within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-
Slide 3: ARCUS Platform Has Multiple Points of Clinical Validation
ARCUS WORKS: ARCUS Platform Has Multiple Points of Clinical Validation Led by Wholly Owned HBV Program with an Emerging Path to Expansion & Phase II Clinical Stage Programs Validating ARCUS Wholly Owned Program: PBGENE-HBV for Chronic Hepatitis B 〉 Viral gene elimination program with over 22 doses d
Slide 4: Successful $75M Financing Fuels Further Development of Lead Programs
Successful $75M Financing Fuels Further Development of Lead Programs While Generating Shareholder Value Through Multiple Clinical Milestones Expected Over Next 12-24 Months Expected First Clinical Data Timing 〉 First-in-Class Mechanism targeting cccDNA elimination PBGENE-HBV 〉 Well Tolerated Safety
Slide 5: Late-Breaking Abstract Presentation PBGENE-HBV at AASLD
Dr. MF Yuen Presented Late Breaking Oral Presentation on PBGENE-HBV at AASLD Phase 1 datasets rarely receive late breaking oral presentations* MF Yuen, MD, PhD Late-Breaking Abstract Presentation Chair Professor of Gastroenterology and Hepatology, Li Shu Fan Medical Foundation Professor in Medicine,
Slide 6: PBGENE-HBV: The First and Only Gene Editor for Chronic Hepatitis B
The First and Only Gene Editor PBGENE-HBV for Chronic Hepatitis B: Designed to Eliminate Clinical Data to Date Demonstrates Repeat Safety Source of Hepatitis B Virus and Meaningful Antiviral Activity Across First Three Cohorts 5
Slide 7: New Rules for a New Modality: Direct Viral Elimination
New Rules for a New Modality: Resetting the Ground Rules for Direct Viral Elimination of Hepatitis B the ONLY Path to Complete Cure PBGENE-HBV First and Only Clinical Stage Program Demonstrating Promising Data with Path Towards Stopping NUCs to Test for Cure Reducing HBsAg is Not Enough: 〉 PBGENE-HB
Slide 8: Large Unmet Need Remains for Patients with Hepatitis B
Current Standard of Care Large Unmet Need Nucleoside Analogs (NUC) and Therapies Remains for Patients in Development Have Never Addressed the with Hepatitis B Root Cause of Hepatitis B and Rarely Cures 7
Slide 9: cccDNA is the Only Source of New Infectious Particles
cccDNA is the Only Source of New Infectious Particles cccDNA is the source of pregenomic RNA (pgRNA) that is cccDNA Integrated HBV DNA necessary for infectious particles (HBV DNA) Hepatocytes Bloodstream HBsAg mRNAs pgRNA Infectious particles (HBV DNA) HBcrAg HBsAg HBeAg Chronic HBV is driven by per
Slide 10: Even with Latest Therapies in Development Functional Cure Remains Elusive
Even with Latest Therapies in Development Functional Cure Remains Elusive: Downstream targeting therapies do not eliminate cccDNA Treatment with NUCs only results in a 1-3% cccDNA Integrated HBV DNA functional cure rate and patients continue Hepatocytes to have an elevated Bloodstream risk of hepato
Slide 11: HBV Cure Requires a Novel Approach Targeting the Viral Replication Source
HBV Cure Requires a Novel Approach Targeting the Viral Replication Source Eliminating cccDNA has a Biologic Rationale for Cure PBGENE HBV 1 Eliminates cccDNA "The ideal therapeutic strategy for curative approaches includes reduction or elimination of the whole cccDNA pool." 2 Inactivates Integrated
Slide 12: ELIMINATE-B Trial Results
ELIMINATE-B Trial Results: Testing PBGENE-HBV the First Clinical Modality Designed to Eliminate cccDNA 11
Slide 13: Phase 1/2a Study Design
Phase 1/2a Study Design Potential for rapid evaluation of safety and efficacy of PBGENE-HBV in 2025 Part 1: Multiple Ascending Dose Escalation Part 2: Dose Expansion Finite Treatment: Patient receives up to 3 dose administrations* Advance optimized dose and schedule to eliminate cccDNA and drive cur
Slide 14: PBGENE-HBV was Well Tolerated with Repeat Dosing Across All Dose Levels
PBGENE-HBV was Well Tolerated with Repeat Dosing Across All Dose Levels Adverse events were predictable and manageable Number of patients experiencing 0.2 mg/kg 0.4 mg/kg 0.8 mg/kg treatment-related: n=3 n=3 n=3 Any Grade 1 AEs 2 3 3 No DLTs have been observed Chills 2 across all 22 doses given2 Fev
Slide 15: Lab Values Below Thresholds for LNP Safety Concerns
Diving Into Most Important Safety Markers: Lab Values Below Thresholds for LNP Safety Concerns Even Following Repeat Administrations Across Cohorts Transient ALT elevations resolved Transient AST elevations Bilirubin fluctuations quickly and were <5X ULN resolved quickly near normal range 120 500 50
Slide 16: PBGENE-HBV: Well Tolerated Across All Three Cohorts
PBGENE-HBV: Well Tolerated Across All Three Cohorts 〉PBGENE-HBV has been well tolerated with repeat doses spanning dose levels of 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg (n=22 doses administered) 〉Adverse events were predictable, manageable, and quickly resolved across broad range of global sites 〉Transa
Slide 17: Clear Antiviral Activity Alongside Durable Responses Through Increasing Dose Levels
Clear Antiviral Activity Alongside Durable Responses Established Through Increasing Dose Levels with Path Towards Stopping NUCs 16
Slide 18: Antiviral Activity Across All Three Patients at Lowest Dose
Antiviral Activity Established Across All Three Patients at Lowest Dose with One Patient Durable 9 Months After First Dose Cohort 1 | 0.2 mg/kg Activity in 3 of 3 patients Durable response in 1 of 3 patients 150 Trend line equation y = -0.1612x + 100 HBsAg (% of baseline) 100 50 0 Weeks After Dose A
Slide 19: Cohort 2: Antiviral Activity and Durable Responses in All Three Patients
At Double the Dose from Cohort 1, Cohort 2 Demonstrated Antiviral Activity and Durable Responses in All Three Patients Cohort 2 | 0.4 mg/kg Activity in 3 of 3 patients Durable response in 3 of 3 patients Trend line equation 150 y = -0.3001x + 100 HBsAg (% of baseline) 100 50 0 Weeks After Dose Admin
Slide 20: Increasing Dose to 0.8 mg/kg Leads to Greater Rate of HBsAg Decline
Data to Date Shows that Increasing Dose to 0.8 mg/kg Leads to a Greater Rate of HBsAg Decline Cohort 3 | 0.8 mg/kg Activity in 3 of 3 patients Dose dependent effect established 150 Trend line equation y = -0.9901x + 100 HBsAg (% of baseline) 100 50 0 Weeks After Dose Administration Cohort 1: Patient
Slide 21: Durable Responses and Dose Dependent Effects Across Dose Levels
Clear Antiviral Activity Alongside Durable Responses and Dose Dependent Effects Established Through Increasing Dose Levels Cohort 1 | 0.2 mg/kg Cohort 2 | 0.4 mg/kg Cohort 3 | 0.8 mg/kg Activity in 3 of 3 patients Activity in 3 of 3 patients Activity in 3 of 3 patients Durable response in 1 of 3 pat
Slide 22: Deep Dive Into Cohort 3 at 0.8 mg/kg
Dose Level 3 | 0.8 mg/kg Deep Dive Into Cohort 3: At 0.8 mg/kg All Three Patients Continue to Demonstrate Deepening Responses Towards Benchmark to Consider Stopping NUCs to Test for Cure Patient 7 Patient 8 Patient 9 700 450 500 400 450 600 400 350 500 350 300 300 HBsAg (IU/mL) HBsAg (IU/mL) HBsAg (
Slide 23: PBGENE-HBV is on Potential Path to Stopping NUCs and Testing For Cure
With Dose Dependent and Durable Antiviral Effects, PBGENE-HBV is on Potential Path to Stopping NUCs and Testing For Cure Repeat dosing designed to drive cumulative Only mechanism targeting cccDNA elimination in antiviral effects and cure development with potential for complete cure 700 Dose #1 600 W
Slide 24: Supportive Biopsy Data Confirms PBGENE-HBV Mechanism of Action
Supportive Biopsy Data Confirms PBGENE-HBV Mechanism of Action Editing Viral DNA 23
Slide 25: Proof of Mechanism: Evidence of PBGENE-HBV Activity on Viral DNA
Hot off The Press - Proof of Mechanism: Evidence of PBGENE-HBV Activity on Viral DNA Preclinical NHP Viral DNA Editing Clinical Biopsy Data (Two Admins at 0.5 mg/kg) (Two Admins at 0.4 mg/kg) Inactivation with indels % Viral DNA Editing 100 28% 80 in remaining DNA 60 40 Elimination Elimination of vi
Slide 26: Measuring the Viral Source with Biopsy
Measuring the Viral Source with Biopsy Participant 5 underwent pre and post treatment biopsy Patient 5 〉 Molecular biopsy data in Patient 5 was taken 3500 to a 44% decline in HBsAg X% after 2 dose administrations and corresponds 3000 editing in 44% 44% 〉 After the third dose administration, PatientD
Slide 27: Next Steps: Planning for Progression Into Part 2 Expansion and Beyond
Next Steps: Planning for Progression Into Part 2 Expansion and Beyond Complete Dosing Stop NUCs, Expand for Cohort 3 Test for Cure to Part 2 All 3 doses expected to Will consider stopping NUCs Expect to dose up to 45 complete in Q1 2026 after observing two sustained, patients between Part 1 and low
Slide 28: What Does Success for ELIMINATE-B Look Like?
What Does Success for ELIMINATE-B Look Like? Two FDA Regulatory Pathways Support Advancement of Therapies in Hepatitis B Current therapies in development have not been able to directly target cccDNA and hence the path towards approval has focused on functional cure GUIDANCE DOCUMENT through HBsAg lo
Slide 29: PBGENE-DMD
PBGENE-DMD Precision’s lead muscle program utilizing novel gene excision approach for majority of patients with Duchenne Muscular Dystrophy (DMD) 28
Slide 30: PBGENE-DMD: A Novel Clinical Candidate with Advantages Beyond Existing Treatments
PBGENE-DMD: A Novel Clinical Candidate with Advantages Beyond Existing Treatments Ideal therapy Microdystrophin Exon Skipping PBGENE-DMD would have: Gene Therapies Therapies Target Product Profile Improved muscle function over time Long-term durable benefit Broadly applicable to patients Corrects hu
Slide 31: PBGENE-DMD Designed to Provide Durable Functional Improvement for 60% of Patients
PBGENE-DMD Designed to Provide Durable Functional Improvement for 60% of Patients with DMD PBGENE-DMD: A single AAV encodes two ARCUS proteins designed to permanently edit a patient’s own DNA sequence, resulting in naturally-expressed, functional dystrophin Up to 60% ARCUS 1 ARCUS 2 of patients have
Slide 32: Near Full Length Dystrophin Protein Has Known Function in Del45-55 Genotype
Near Full Length Dystrophin Protein Has Known Function in Individuals with Dystrophin Del45-55 Genotype Lifespan: Lifespan: • Early death in late teens or 20s • Can live into 60-70s1-3 Clinical Presentation: Clinical Presentation: • Progressive muscle weakness leading • Asymptomatic or mild to loss
Slide 33: PBGENE-DMD Resulted in Increased Dystrophin Protein Levels Over Time
PBGENE-DMD Resulted in Increased Dystrophin Protein Levels Over Time, Exceeding Expected Therapeutic Threshold Heart Calf Quadricep 20 30 25 25 20 Dystrophin Restoration (%) Dystrophin Restoration (%) Dystrophin Restoration (%) 15 20 15 10 15 10 10 5 5 5 0 0 0 Treated disease mice Treated disease mi
Slide 34: PBGENE-DMD Significantly Improved Muscle Function
PBGENE-DMD Significantly Improved Muscle Function and Demonstrated Potential for Long-Term Durability Untreated Untreated PBGENE-DMD PBGENE-DMD Diseased Healthy (1x1014 vg/kg) (3x1013 vg/kg) 200% Normalized Force/BW 150% to Untreated Disease 100% 50% 0% 〉Improved muscle function observed from 3 to 6
Slide 35: Phase I/II/III Study Designed for Safety and Speed
Phase I/II/III Study Designed for Safety and Speed Phase I/II – Establish Safety and Efficacy Planned Pivotal Trial Single-Dose Level Design Final dose to be aligned with regulators (e.g., 1e14 vg/kg) Plan: 〉Treat a total of 35 to 40 〉Enroll 5-8 ambulatory patients across multiple Move to patients a
Slide 36: Successful $75M Financing Fuels Further Development of Lead Programs
Successful $75M Financing Fuels Further Development of Lead Programs While Generating Shareholder Value Through Multiple Clinical Milestones Expected Over Next 12-24 Months Expected First Clinical Data Timing 〉 First-in-Class Mechanism targeting cccDNA elimination PBGENE-HBV 〉 Well Tolerated Safety
Slide 37: Appendix
PRECISION BIOSCIENCES Appendix my 36
Slide 38: Treatment Goal Today: ≥30% Functional Cure Rate Has Remained Elusive
Treatment Goal Today: ≥30% Functional Cure Rate Set By HBV Experts Has Remained Elusive AASLD, American Association for the Study of Liver Diseases; DNA, deoxyribonucleic acid; EASL, European Professional Organization for Hepatology; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. 37
Slide 39: Enrolling a Real-World Population of HBeAg Negative Patients (Cohort 1)
Dose Level 1 | 0.2 mg/kg Enrolling a Real-World Population of HBeAg Negative Patients Across Range of Key Demographics and Baseline Characteristics Cohort 1 (0.2 mg/kg) Patient 1 Patient 2 Patient 3 Sex Male Male Male Age (years) 40 39 44 Ethnicity/Race Caucasian Caucasian Caucasian Region of Origin
Slide 40: Enrolling a Real-World Population Across Key Demographics (Cohort 2)
Dose Level 2 | 0.4 mg/kg Enrolling a Real-World Population Across Range of Key Demographics and Baseline Characteristics Cohort 2 (0.4 mg/kg) Patient 4 Patient 5 Patient 6 Sex Male Male Male Age (years) 50 45 52 Ethnicity/Race Asian Asian Asian Region of Origin Asia Asia Asia Time with HBV (years) 3
Slide 41: Enrolling a Real-World Population Across Key Demographics (Cohort 3)
Dose Level 3 | 0.8 mg/kg Enrolling a Real-World Population Across Range of Key Demographics and Baseline Characteristics Cohort 3 (0.8 mg/kg) Patient 7 Patient 8 Patient 9 Sex Male Male Male Age (years) 64 53 54 Native Hawaiian or Other Ethnicity/Race Asian Asian Pacific Islander Region of Origin As
Slide 42: PBGENE-HBV Activity Independent of HBsAg Baseline Levels
PBGENE-HBV Activity Independent of HBsAg Baseline Levels Cohort 1 Cohort 2 Cohort 34 Patient 2 – Baseline HBsAg Patient 5 – Baseline HBsAg Patient 7 – Baseline HBsAg 11,813 IU/mL 3,159 IU/mL 651 IU/mL HBsAg Change Note natural HBsAg From Baseline at fluctuations including Nadir During Course -69% -6
Slide 43: PBGENE-DMD Designed to Produce a Near Full-Length Dystrophin Protein
PBGENE-DMD Designed to Produce a Near Full-Length Dystrophin Protein, Demonstrated to be Functional in Humans H1 H2 H3 H4 Full-length ABD R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 CR CT Dystrophin Full-length Dystrophin Functional ABD H1 R1 R2 R3 H2 R4 R5
Precision BioSciences — Corporate Update (November 2025) on 6ix